Preclinical studies performed in appropriate models could help identify optimal timing of combined chemotherapy and immunotherapy.
cancer therapy
chemotherapy
combination treatment
immune checkpoint inhibitors
preclinical models
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
08
06
2023
accepted:
23
08
2023
medline:
26
9
2023
pubmed:
25
9
2023
entrez:
25
9
2023
Statut:
epublish
Résumé
Immune checkpoint inhibitors (ICI) have been revolutionary in the field of cancer therapy. However, their success is limited to specific indications and cancer types. Recently, the combination treatment of ICI and chemotherapy has gained more attention to overcome this limitation. Unfortunately, many clinical trials testing these combinations have provided limited success. This can partly be attributed to an inadequate choice of preclinical models and the lack of scientific rationale to select the most effective immune-oncological combination. In this review, we have analyzed the existing preclinical evidence on this topic, which is only limitedly available. Furthermore, this preclinical data indicates that besides the selection of a specific drug and dose, also the sequence or order of the combination treatment influences the study outcome. Therefore, we conclude that the success of clinical combination trials could be enhanced by improving the preclinical set up, in order to identify the optimal treatment combination and schedule to enhance the anti-tumor immunity.
Identifiants
pubmed: 37744323
doi: 10.3389/fimmu.2023.1236965
pmc: PMC10512939
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1236965Informations de copyright
Copyright © 2023 Berckmans, Ceusters, Vankerckhoven, Wouters, Riva and Coosemans.
Déclaration de conflit d'intérêts
Author RW was employed by the company Oncoinvent AS. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
Transl Oncol. 2021 Jun;14(6):101076
pubmed: 33770618
Cancer Immunol Res. 2015 May;3(5):436-43
pubmed: 25941355
ILAR J. 2021 Dec 31;62(1-2):66-76
pubmed: 35421235
iScience. 2020 May 22;23(5):101056
pubmed: 32344378
Animal Model Exp Med. 2021 Mar 29;4(2):87-103
pubmed: 34179717
Lancet Oncol. 2021 Jul;22(7):931-945
pubmed: 34051178
Eur J Cancer. 2019 May;113:41-44
pubmed: 30965214
Front Cell Dev Biol. 2021 May 20;9:660969
pubmed: 34095125
Neurosurgery. 2021 Jan 13;88(2):E205-E215
pubmed: 33289503
Nat Rev Clin Oncol. 2020 Dec;17(12):725-741
pubmed: 32760014
Front Immunol. 2018 Jul 27;9:1739
pubmed: 30100909
Nat Rev Immunol. 2008 Jan;8(1):59-73
pubmed: 18097448
JAMA Oncol. 2020 Oct 1;6(10):1571-1580
pubmed: 32880601
Lancet Oncol. 2022 Jul;23(7):876-887
pubmed: 35636444
Br J Cancer. 2018 Feb 6;118(3):312-324
pubmed: 29123260
Ann Oncol. 2017 Oct 01;28(10):2595-2605
pubmed: 28945830
Nat Med. 2021 Jul;27(7):1250-1261
pubmed: 34239134
Nat Rev Drug Discov. 2021 Mar;20(3):168-169
pubmed: 33177720
Nat Commun. 2015 Feb 27;6:6169
pubmed: 25721094
Cancer Res. 2017 Apr 15;77(8):2029-2039
pubmed: 28202521
Cancer Discov. 2021 Jun;11(6):1353-1367
pubmed: 33712487
Int J Mol Sci. 2020 Jul 15;21(14):
pubmed: 32679922
J Innate Immun. 2021;13(1):49-59
pubmed: 32906119
Sci Rep. 2020 Apr 27;10(1):7078
pubmed: 32341383
Oncogene. 2019 Jun;38(25):4902-4914
pubmed: 30872793
Oncotarget. 2020 Jul 14;11(28):2686-2701
pubmed: 32733642
Int J Nanomedicine. 2020 Jul 27;15:5279-5288
pubmed: 32801691
Annu Rev Immunol. 2013;31:51-72
pubmed: 23157435
Ann Oncol. 2016 Jul;27(7):1190-8
pubmed: 26912558
Nat Protoc. 2022 Sep;17(9):2108-2128
pubmed: 35859135
JCI Insight. 2018 Apr 19;3(8):
pubmed: 29669928
J Clin Oncol. 2021 Jun 10;39(17):1842-1855
pubmed: 33891472
J Cell Physiol. 2019 Nov;234(11):19866-19874
pubmed: 30941773
Lancet Oncol. 2021 Sep;22(9):1275-1289
pubmed: 34363762
Nat Rev Drug Discov. 2012 Feb 03;11(3):215-33
pubmed: 22301798
Front Immunol. 2023 Feb 27;14:1126969
pubmed: 36923404
Ann Oncol. 2021 Aug;32(8):983-993
pubmed: 34272041
Lancet Oncol. 2016 Nov;17(11):1497-1508
pubmed: 27745820
Am J Cancer Res. 2020 Feb 01;10(2):473-490
pubmed: 32195021
Cancer Cell. 2015 Dec 14;28(6):690-714
pubmed: 26678337
Cancers (Basel). 2020 Mar 20;12(3):
pubmed: 32245016
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
PLoS One. 2013 Apr 23;8(4):e61895
pubmed: 23626745
Vet Immunol Immunopathol. 2022 Jan;243:110362
pubmed: 34826685
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Oncotarget. 2017 Jun 9;8(33):54775-54787
pubmed: 28903381
AAPS J. 2021 Mar 7;23(2):39
pubmed: 33677681
Lancet Oncol. 2021 Jul;22(7):1034-1046
pubmed: 34143970
N Engl J Med. 2020 Feb 27;382(9):810-821
pubmed: 32101663
Cancers (Basel). 2021 Nov 24;13(23):
pubmed: 34885008
Mamm Genome. 2022 Mar;33(1):230-240
pubmed: 34476572
Bull Exp Biol Med. 2011 May;151(1):99-102
pubmed: 22442812
Ann Oncol. 2018 Jan 1;29(1):84-91
pubmed: 29228097
J Immunother Cancer. 2022 Feb;10(2):
pubmed: 35210305
Adv Drug Deliv Rev. 2021 May;172:296-313
pubmed: 33705879
Sci Immunol. 2017 Jan 6;2(7):
pubmed: 28783667
Diagnostics (Basel). 2020 Aug 31;10(9):
pubmed: 32878340